This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Prahalada, S. Articles by van Zwieten, M. J. Search for Related Content PubMed PubMed Citation Articles by Prahalada, S. Articles by van Zwieten, M. J. Social Bookmarking                         What's this?

Pharmacological and Toxicological Effects of Chronic Porcine Growth Hormone Administration in Dogs

Departments of Safety Assessment, Merck Research Laboratories (MRL), West Point, Pennsylvania 19486, and Railway, New Jersey 07065, USA

Lea G. Stabinski

Departments of Safety Assessment, Merck Research Laboratories (MRL), West Point, Pennsylvania 19486, and Railway, New Jersey 07065, USA

Howard Y. Chen

Departments of Biochemistry and Physiology, Merck Research Laboratories (MRL), West Point, Pennsylvania 19486, and Railway, New Jersey 07065, USA

Richard E. Morrissey

Schering-Plough, Lafayette, New Jersey 07848, USA

Georges De Burlet

Riom, France, Lafayette, New Jersey 07848, USA

Dan Holder

Departments of Biometrics, Merck Research Laboratories (MRL), West Point, Pennsylvania 19486, and Railway, New Jersey 07065, USA

Darryl H. Patrick

Departments of Safety Assessment, Merck Research Laboratories (MRL), West Point, Pennsylvania 19486, and Railway, New Jersey 07065, USA

Chennekatu P. Peter

Departments of Safety Assessment, Merck Research Laboratories (MRL), West Point, Pennsylvania 19486, and Railway, New Jersey 07065, USA

Matthew J. van Zwieten

Departments of Safety Assessment, Merck Research Laboratories (MRL), West Point, Pennsylvania 19486, and Railway, New Jersey 07065, USA

The purpose of this study was to evaluate the pharmacological and toxicological effects of exogenous GH administration in normal adult dogs. Because porcine GH (pGH) is structurally identical to canine GH, pGH was selected for a 14-wk study in dogs. Thirty-two dogs (<2 yr) were randomized to 4 groups (4 dogs/sex/group); 1 group was treated with the vehicle and 3 groups received pGH at 0.025. 0.1, or 1.0 IU/kg/day subcutaneously. Daily clinical signs and weekly body weights were recorded. Hematology, serum biochemistry, urinalyses, electrocardiograms, and ophthalmoscopic examinations were done. Serum GH, insulin-like growth factor-1 (IGF-1), insulin, thyroxine (T4), triiodothyronine (T3), and Cortisol levels were determined. Necropsies were performed, organs weighed, and tissues were fixed and processed for light microscopic examination. Porcine GH caused increased body weight gain (p 0.05) through the mid dose; the mean weight gains at study termination in mid- and high-dose groups were 2.8 kg and 4.7 kg, respectively, compared to 0.4 kg and 0.8 kg in control and low-dose groups, respectively. Dose-related increased weights of liver, kidney, thyroid, pituitary gland, skeletal muscle, and adrenal gland were noted. In pGH-treated dogs, increased skin thickness seen grossly correlated histologically with increased dermal collagen. There was no gross or histomorphological evidence of edema. There were dose-related increased serum IGF-1 levels (2–10-fold; p 0.05) that correlated with the elevated serum GH levels in pGH-treated dogs. Also, increased serum insulin levels (p 0.05) through the mid dose were seen throughout the study. In high-dose dogs, the insulin levels remained elevated over 24 hr postdose. The serum glucose levels in fasted dogs remained within the control range and there was no chronic hyperglycemia based on glycosylated hemoglobin levels. Renal glomerular changes, significant polyuria with decreased urine specific gravity, and increased serum insulin levels suggested that the dogs had early insulin-resistant diabetes. There was minimal or no biologically significant effect of pGH on serum T3, T4, and Cortisol levels in dogs. Other serum biochemical changes in pGH-treated dogs included decreased urea nitrogen and creatinine, and increased potassium, cholesterol, and triglycerides. Significant increases in serum calcium and phosphorous levels and alkaline phosphatase activity (bone isozyme) correlated with the histological changes in bone. In pGH-treated dogs, there was a dose-related normochromic, normocytic, nonregenerative anemia. The changes described above, except for the anemia, are related to either anabolic or catabolic effects of high doses of GH. Based on this study, it is concluded that the dog is a good model in which to evaluate the safety of GH secretagogues as well as compounds with GH-like activity.

Key Words: Insulin-like growth factor-1 (IGF-1) • levels • insulin levels • insulin resistance • body weight change • erythroid depletion • hepatic change • anabolic effects • catabolic effects

Toxicologic Pathology, Vol. 26, No. 2, 185-200 (1998)
DOI: 10.1177/019262339802600201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. R. Edmondson, S. P. Thumiger, G. A. Werther, and C. J. Wraight Epidermal Homeostasis: The Role of the Growth Hormone and Insulin-Like Growth Factor Systems Endocr. Rev., December 1, 2003; 24(6): 737 - 764. [Abstract] [Full Text] [PDF]

				R. Draghia-Akli, K. K. Cummings, A. S. Khan, P. A. Brown, and R. H. Carpenter Effects of plasmid-mediated growth hormone releasing hormone supplementation in young, healthy Beagle dogs J Anim Sci, September 1, 2003; 81(9): 2301 - 2310. [Abstract] [Full Text] [PDF]

				Y.-T. Shen, J. J. Lynch, R. J. Hargreaves, and R. J. Gould A Growth Hormone Secretagogue Prevents Ischemic-Induced Mortality Independently of the Growth Hormone Pathway in Dogs with Chronic Dilated Cardiomyopathy J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 815 - 820. [Abstract] [Full Text] [PDF]

				S. Molon-Noblot, P. Laroque, S. Prahalada, L. G. Stabinski, C. P. Peter, P. Duprat, and M. J. Van Zwieten Morphological Changes in the Kidney of Dogs Chronically Exposed to Exogenous Growth Hormone Toxicol Pathol, July 1, 2000; 28(4): 510 - 517. [Abstract] [PDF]

				C. A. Bondy Growth Hormone Augmentation--A New Era? Toxicol Pathol, March 1, 1998; 26(2): 213 - 216. [PDF]